Identification of driver mutations in lung cancer: first step in personalized cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2009 • 7,749 citations

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

2012 • 7,135 citations

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

2006 • 5,595 citations

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

2010 • 5,268 citations

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

2012 • 5,195 citations

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

2007 • 5,137 citations

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 • 4,320 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 • 4,293 citations

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

2010 • 4,281 citations

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

2009 • 3,957 citations

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

2011 • 3,882 citations

EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 • 3,807 citations

Comprehensive genomic characterization of squamous cell lung cancers

2012 • 3,654 citations

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

2005 • 3,450 citations

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

2006 • 3,441 citations

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

2011 • 3,196 citations

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

2008 • 3,092 citations

Epidermal growth factor receptor mutations in lung cancer

2007 • 2,966 citations

Somatic mutations affect key pathways in lung adenocarcinoma

2008 • 2,653 citations

Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma

1994 • 2,375 citations

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

2005 • 2,285 citations

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

2009 • 2,274 citations

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

2009 • 1,805 citations

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

2008 • 1,606 citations

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

2007 • 1,571 citations

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

2005 • 1,510 citations

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

2011 • 1,492 citations

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

2012 • 1,480 citations

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

2007 • 1,234 citations

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

2012 • 1,220 citations

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

2010 • 1,196 citations

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

2010 • 1,163 citations

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

2012 • 1,029 citations

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

2005 • 965 citations

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

2009 • 913 citations

The BATTLE Trial: Personalizing Therapy for Lung Cancer

2011 • 860 citations

New driver mutations in non-small-cell lung cancer

2012 • 829 citations

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

2010 • 794 citations

KIF5B-RET fusions in lung adenocarcinoma

2012 • 785 citations

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

2008 • 735 citations

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

2005 • 704 citations

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

1997 • 703 citations

Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

2008 • 675 citations

Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

2011 • 668 citations

Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions

2005 • 636 citations

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

2011 • 587 citations

Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer

2005 • 554 citations

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

2002 • 554 citations

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

2008 • 542 citations

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

2008 • 524 citations

RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer

2012 • 499 citations

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

1993 • 482 citations

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2011 • 470 citations

EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

2008 • 465 citations

Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer

2006 • 439 citations

Identification of Novel Isoforms of theEML4-ALKTransforming Gene in Non–Small Cell Lung Cancer

2008 • 428 citations

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

2011 • 416 citations

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

2008 • 409 citations

Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features

2006 • 398 citations

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

2002 • 396 citations

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

2011 • 375 citations

Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities

2012 • 315 citations

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies

2009 • 304 citations

Roles of Fibroblast Growth Factor Receptors in Carcinogenesis

2010 • 293 citations

SOX2 Is an Oncogene Activated by Recurrent 3q26.3 Amplifications in Human Lung Squamous Cell Carcinomas

2010 • 293 citations

Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

2011 • 275 citations

PIK3CA mutation status in Japanese lung cancer patients

2006 • 273 citations

Prevalence and specificity of LKB1 genetic alterations in lung cancers

2007 • 268 citations

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

2012 • 266 citations

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

2009 • 259 citations

EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases

2009 • 257 citations

Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

2008 • 241 citations

The type III epidermal growth factor receptor mutation

2001 • 241 citations

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

2002 • 233 citations

Molecular pathology of lung cancer: key to personalized medicine

2012 • 232 citations

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).

2011 • 207 citations

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC

2008 • 207 citations

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

2011 • 201 citations

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

2011 • 199 citations

Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung

2008 • 183 citations

Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).

2012 • 164 citations

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

2012 • 164 citations

EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas

2012 • 157 citations

Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma

2011 • 134 citations

Insulin-like Growth Factor Receptor 1 (IGF1R) Gene Copy Number Is Associated With Survival in Operable Non–Small-Cell Lung Cancer: A Comparison Between IGF1R Fluorescent In Situ Hybridization, Protein Expression, and mRNA Expression

2010 • 125 citations

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).

2010 • 121 citations

Tumour molecular profiling for deciding therapy—the French initiative

2012 • 83 citations

Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)

2012 • 72 citations

Epidermal growth factor receptor immunohistochemistry

2008 • 71 citations

Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)

2012 • 56 citations

Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors

2012 • 50 citations

A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

2010 • 50 citations

Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Non–Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab

2010 • 44 citations

Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).

2012 • 37 citations

LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations

2012 • 18 citations

9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC)

2011 • 10 citations